Loading...
XETR
FME
Market cap12bUSD
Jun 18, Last price  
41.26EUR
1D
-0.29%
1Q
9.33%
Jan 2017
-48.71%
Name

Fresenius Medical Care AG & Co KGaA

Chart & Performance

D1W1MN
XETR:FME chart
P/E
20.60
P/S
0.57
EPS
2.00
Div Yield, %
3.49%
Shrs. gr., 5y
14.15%
Rev. gr., 5y
2.04%
Revenues
19.34b
-0.61%
5,717,514,4996,439,636,1026,666,871,7637,623,256,1037,850,289,0469,063,019,1319,872,028,54310,434,945,23110,580,072,09813,019,603,52015,309,579,08017,030,495,24017,784,000,00016,547,000,00017,477,000,00017,859,000,00017,619,000,00019,398,000,00019,453,617,00019,335,909,000
Net income
538m
+7.80%
384,120,523406,687,076491,857,953587,319,812621,978,678735,746,932826,448,868897,393,757803,760,140859,366,200941,185,1401,181,894,1201,280,000,0001,982,000,0001,200,000,0001,164,377,000969,308,000673,405,000498,997,000537,913,000
CFO
2.39b
-9.23%
565,944,370687,853,712822,751,819730,119,339934,568,4401,028,693,1871,115,661,3001,541,817,0961,473,565,0841,530,411,9601,792,733,6002,034,797,6002,192,000,0002,062,000,0002,567,000,0004,233,000,0002,489,000,0002,167,000,0002,628,801,0002,386,144,000
Dividend
May 22, 20261.49 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fresenius Medical Care AG & Co. KGaA, established in Bad Homburg, Germany, in 1996, operates as a global provider of dialysis care and associated services. The company boasts an extensive international footprint, managing 4,171 outpatient dialysis clinics across approximately 150 countries (as of February 23, 2022), with significant operations in Germany and North America. Its comprehensive service portfolio includes in-clinic dialysis treatments, supported by laboratory and diagnostic services, alongside robust home dialysis programs that provide essential materials, training, patient monitoring, and supply delivery. Fresenius Medical Care also contracts with hospitals in the United States to deliver dialysis care to hospitalized patients suffering from acute kidney failure or end-stage renal disease. Beyond core dialysis, the company offers specialized medical services in vascular, cardiovascular, endovascular, nephrology, and cardiology. A key player in medical technology, Fresenius Medical Care actively develops, manufactures, and distributes a broad spectrum of dialysis products. This range encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, hemodialysis concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. They also produce non-dialysis items like acute cardiopulmonary and apheresis products. The firm is additionally involved in the pharmaceutical sector, developing, acquiring, and licensing renal medications and supplies for direct distribution to patients' homes or dialysis clinics. Products are sold to dialysis clinics, hospitals, and specialized treatment centers through direct channels, local sales forces, and a network of independent distributors, dealers, and agents.
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT